Clinical Trials
16 trialsNCT00923507 2026-06-04
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04840602 2026-06-03
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05006716 2026-06-03
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT07231952 2026-06-03
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07387471 2026-05-29
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
NCT04728893 2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT01804686 2026-05-08
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT02269592 2026-05-07
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Recruiting
NCT05099471 2026-05-05
VIWA-1
University of Ulm
Phase 2 Recruiting
NCT07249905 2026-05-04
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT05294731 2026-04-17
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
Phase 1/2 Recruiting
NCT05131022 2026-04-14
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06544265 2026-04-14
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
Phase 1 Recruiting
NCT06561347 2026-03-31
ZEBRA
Massachusetts General Hospital
Phase 2 Recruiting
NCT04830137 2026-03-20
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT06510491 2026-03-13
Epcoritamab in Previously Treated WM
Beth Israel Deaconess Medical Center
Phase 2 Recruiting